NEW YORK (GenomeWeb News) – Berg Pharma will use its Integrative Biology platform to identify drug targets and biomarkers in clinical samples from the Parkinson's Institute of Sunnyvale, Calif., under a partnership announced today.
A 23andMe and Parkinson's Institute team has tracked down two new risk loci for Parkinson's disease and verified many more through a web-based genome-wide association study involving more than 3,400 cases and nearly 30,000 controls.
University of Illinois at Urbana-Champgain, 23andMe, Michael J. Fox Foundaton for Parkinson's Research, Parkinson's Institute and Clinical Center, SeqWright, Roche NimbleGen, Chronix Biomedical, Genome Atlantic, Agilent Technologies
Working to enroll thousands of individuals with Parkinson's into an online community, Sergey Brin, 23andMe, the Michael J. Fox Foundation, and the Parkinson's Institute are teaming up to offer 23andMe services at a bargain price.